1
Kevin Rodzinak
Vadim Y Dudkin, Mark E Fraley, Kenneth L Arrington, Mark E Layton, Alexander J Reif, Kevin J Rodzinak, Joseph E Pero: Positive allosteric modulators of MGLUR2. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, March 31, 2015: US08993779 (1 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


2
Kenneth L Arrington, Edward J Brnardic, Vadim Y Dudkin, Mark E Fraley, Shaei Y Huang, Cheng Wang: Inhibitors of checkpoint kinases. Merck & Co, Li Su, David A Muthard, March 10, 2009: US07501435 (1 worldwide citation)

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of t ...


3
Vadim Y Dudkin, Mark E Fraley, Cheng Wang, Robert M Garbaccio, Douglas C Beshore, Scott K Kuduk, Jason W Skudlarek: Ether benzotriazole derivatives. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, March 10, 2015: US08975286 (1 worldwide citation)

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and d ...


4
Christopher D Cox, Vadim Y Dudkin, Jeffrey Kern, Mark E Layton, Izzat T Raheem: Pyrimidine PDE10 inhibitors. Merck Sharp & Dohme, Sylvia A Ayler, John C Todaro, June 23, 2015: US09062059

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatr ...


5
Christopher D Cox, Vadim Y Dudkin, June J Kim, Scott D Kuduk, Carol A McVean, Thomas Reger, Justin T Sheen, Thomas Steele: Triazolyl PDE10 inhibitors. Merck Sharp & Dohme, Sylvia A Ayler, John C Todaro, December 1, 2015: US09200001

The present invention is directed to substituted triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological an ...


6
Scott D Kuduk, Christopher D Cox, Vadim Y Dudkin, Carol A McVean, Thomas S Reger, Justin T Steen: Secondary alcohol substituted triazoles as PDE10 inhibitors. Merck Sharp & Dohme, Sylvia A Ayler, John C Todaro, August 30, 2016: US09428492

The present invention is directed to secondary alcohol substituted triazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treatin ...


7
Kenneth L Arrington, Edward J Brnardic, Vadim Y Dudkin, Mark E Fraley, Shaei Y Huang, Cheng Wang: Inhibitors of checkpoint kinases. Merck And Co, November 1, 2007: US20070254879-A1

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of t ...


8
Kenneth L Arrington, Vadim Y Dudkin, Mark E Fraley, Jacob M Hoffman, Constantine Kreatsoulas, Cheng Wang: Inhibitors of checkpoint kinases. Merck And Co, September 17, 2009: US20090233896-A1

The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of t ...


9
Vadim Y Dudkin, Mark E Fraley, Cheng Wang, Robert M Garbaccio, Douglas C Beshore, Scott K Kuduk, Jason W Skudlarek: Ether benzotriazole derivatives. June 14, 2012: US20120149677-A1

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and d ...


10
Kenneth L Arrington, Vadim Y Dudkin, Mark E Fraley, Robert M Garbaccio, George D Hartman, Shaei Y Huang, Constantine Kreatsoulas, Edward S Tasber: Inhibitors of Checkpoint Kinases. Merck And Co, October 15, 2009: US20090258852-A1

The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in nee ...



Click the thumbnails below to visualize the patent trend.